Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs

PHASE3CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Stomach UlcerDuodenal Ulcer
Interventions
DRUG

Lansoprazole

Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.

DRUG

Gefarnate

Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.

Trial Locations (68)

Unknown

Kasugai-shi

Yotsukaido-shi

Matsuyama

Fukui-shi

Chikushi-gun

Fukuoka

Kurume-shi

Munakata-shi

Onga-gun

Gifu

Maebashi

Higashihiroshima-shi

Kure-shi

Asahikawa-shi

Chitose-shi

Sapporo

Kato-shi

Nishinomiya-shi

Hitachi-Naka

Yuki-shi

Hakusan-shi

Komatsu-shi

Takamatsu

Kagoshima

Kamakura-shi

Kawasaki-shi

Sagamihara-shi

Yamato-shi

Yokohama

Kochi

Susaki-shi

Kumamoto

Kyoto

Ise-shi

Shima-shi

Yokkaichi-shi

Sendai

Ebino-shi

Miyazaki

Miyazaki-gun

Matsumoto-shi

Omura-shi

Niigata

Beppu-shi

Okayama

Daito-shi

Osaka

Sakai-shi

Ogi-shi

Saga

Hanyu-shi

Sunto-gun

Shimotsuke-shi

Naruto-shi

Tokushima

Chuo-ku

Hachioji-shi

Kiyose-shi

Machida-shi

Meguro-ku

Nishi-Tokyo-shi

Shibuya-ku

Shinjuku-ku

Toshima-ku

Tottori-shi

Yonago-shi

Shimonoseki-shi

Yanai-shi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY